1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
A medicine company has recalled a drug because it contained an unlisted blood pressure medication.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
4 citations
,
October 2013 in “PLoS ONE” Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.
February 2023 in “Reactions Weekly”
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery”
May 2026 in “Frontiers in Immunology” Bimekizumab effectively treats scalp cellulitis and improves quality of life.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
September 2025 in “Arthritis Research & Therapy” BMS-470539 reduces skin fibrosis and inflammation.
21 citations
,
December 2014 in “Clinics in dermatology” Squaric acid dibutylester effectively treats alopecia areata.
July 2025 in “Scientific Reports” Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.
2 citations
,
February 2004 in “Biopolymers” 4-(4-Phenoxybenzoyl)benzoic acid derivatives can both increase and decrease certain types of reactive oxygen species, and may be relevant to hair loss.
December 2024 in “Egyptian Poultry Science” Ivermectin 0.1% is the best and safest topical treatment for rabbit mange.
1 citations
,
February 2014 in “Archiv Der Pharmazie” Carbamates may help treat androgen-dependent conditions by changing how certain lipid enzymes are produced.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
39 citations
,
August 1998 in “FEBS Letters” Two new enzymes, PAD-R11 and PAD-R4, were cloned and showed activity, with PAD-R11 resembling epidermal enzymes.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
April 2025 in “European Journal of Pharmaceutics and Biopharmaceutics” The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.
July 2024 in “Reactions Weekly”
53 citations
,
October 2012 in “The FASEB Journal” Bimatoprost, a glaucoma medication, may also help treat hair loss.
13 citations
,
July 2011 in “Journal of Dermatological Treatment” Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.
10 citations
,
November 2014 in “Sexual medicine reviews” Effective, well-tolerated, and affordable treatments are needed for recurrent ischemic priapism.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” RPGRIP1L helps skin cells stick together by blocking PKCβII, which can prevent skin blistering like in pemphigus.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
3 citations
,
November 2005 in “British Journal of Dermatology” A man with alopecia universalis regrew hair temporarily after a bone treatment.
11 citations
,
August 2021 in “Stem Cell Research & Therapy” Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.